The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents
Open accessAbstract
BMS-232632 is an azapeptide human immunodeficiency virus type 1 (HIV-1) protease (Prt) inhibitor that exhibits potent anti-HIV activity with a 50% effective concentration (EC 50) of 2.6 to 5.3 nM and an EC 90 of 9 to 15 nM in cell culture. Proof-of-principle studies indicate that BMS-232632 blocks the cleavage of viral precursor proteins in HIV-infected cells, proving that it functions as an HIV Prt inhibitor. Comparative studies showed that BMS-232632 is generally more potent than the five currently approved HIV-1 Prt inhibitors. Furthermore, BMS-232632 is highly selective for HIV-1 Prt and exhibits cytotoxicity only at concentrations 6,500- to 23,000-fold higher than that required for anti-HIV activity. To assess the potential of this inhibitor when used in combination with other antiretrovirals, BMS-232632 was evaluated for anti-HIV activity in two-drug combination studies. Combinations of BMS-232632 with either stavudine, didanosine, lamivudine, zidovudine, nelfinavir, indinavir, ritonavir, saquinavir, or amprenavir in HIV-infected peripheral blood mononuclear cells yielded additive to moderately synergistic antiviral effects. Importantly, combinations of drug pairs did not result in antagonistic anti-HIV activity or enhanced cytotoxic effects at the highest concentrations used for antiviral evaluation. Our results suggest that BMS-232632 may be an effective HIV-1 inhibitor that may be utilized in a variety of different drug combinations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Cited by
Organic Carbamates in Drug Design and Medicinal Chemistry
Ghosh, A. K., & Brindisi, M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501371s · Cited by 739
In silico methods and tools for drug discovery
Shaker, B., Ahmad, S., Lee, J., Jung, C., & Na, D. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104851 · Cited by 607
Molina, J.-M., Andrade-Villanueva, J., Echevarria, J., Chetchotisakd, P., Corral, J., David, N., Moyle, G., Mancini, M., Percival, L., Yang, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61081-8 · Cited by 486
Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance
Wensing, A. M. J., van Maarseveen, N. M., & Nijhuis, M. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.003 · Cited by 339
Synthesis of chiral pharmaceutical intermediates by biocatalysis
Patel, R. N. (2008) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2007.10.031 · Cited by 329
Metadata
- Authors
- Robinson, B. S., Riccardi, K. A., Gong, Y.-F., Guo, Q., Stock, D. A., Blair, W. S., Terry, B. J., Deminie, C. A., Djang, F., Colonno, R. J., & Lin, P.-F.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2000-08
- Volume
- 44
- Issue
- 8
- Pages
- 2093-2099
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2096099963
- Cited by
- 198
- References
- 1
- FWCI
- 7.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents. https://app.cochat.ai/papers/10.1128/aac.44.8.2093-2099.2000
- The paper
- Robinson, B. S., Riccardi, K. A., Gong, Y.-F., Guo, Q., Stock, D. A., Blair, W. S., Terry, B. J., Deminie, C. A., Djang, F., Colonno, R. J., & Lin, P.-F. (2000). BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.44.8.2093-2099.2000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.